Predictors of cognitive impairment in an early stage Parkinson's disease cohort

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 351-359

  Hu, Michele T M ^a,b   Szewczyk Królikowski, Konrad ^a   Tomlinson, Paul ^a   Nithi, Kannan ^b   Rolinski, Michal ^a   Murray, Clara ^c   Talbot, Kevin ^a,b   Ebmeier, Klaus P ^d   Mackay, Clare E ^a,d   Ben Shlomo, Yoav ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Milton Keynes Neuro Rehabilitation Unit   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Dementia; Mild cognitive impairment; Mini Mental State Examination; Montreal Cognitive Assessment; Parkinson's disease

Indexed keywords

ADULT; AGED; ANXIETY DISORDER; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE CLASSIFICATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; ORIENTATION; PARKINSON DISEASE; PRIORITY JOURNAL; RECALL; SMELLING; ALZHEIMER DISEASE; COHORT ANALYSIS; COMPLICATION; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS;

EID: 84896128126     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25748     Document Type: Article

References (71)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
2. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.
3. Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:1136-1142.
4. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-1713.
5. Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:371-378.
6. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011;26:629-636.
7. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.
8. Liepelt-Scarfone I, Graeber S, Feseker A, et al. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease [serial online]. Parkinsons Dis 2011;2011:540843.
9. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814-1824.
10. Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013;28:626-633.
11. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013;70:580-586.
12. Poletti M, Frosini D, Ceravolo R, Bonuccelli U. Mild cognitive impairment in de novo Parkinson's disease according to movement disorder guidelines [letter]. Mov Disord 2012;27:1706; author reply 1707.
13. Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:601-606.
14. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
15. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(pt 7):1787-1798.
16. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year, longitudinal study. J Geriatr Psychiatry Neurol 2005;18:149-154.
17. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
18. Emre M, Aarsland D, Brown RG, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;12:1689-1707.
19. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007;22:2314-2324.
20. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
21. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
22. Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal Cognitive Assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord 2008;23:1043-1046.
23. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738-1745.
24. Barton B, Grabli D, Bernard B, et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord 2012;27:248-253.
25. Di Battista ME, Giustini P, Bernardi S, Stirpe P, Vanacore N, Meco G. A simplified algorithm may lead to overestimate dementia in PD. A clinical and epidemiological study using criteria for PD-D proposed by the Movement Disorders Task Force. J Neural Transm 2011;118:1609-1612.
26. Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson's disease. Mov Disord 2012;27:1125-1128.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
28. EuroQoL Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
29. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
30. Snaith RP, Bridge GW, Hamilton M. The Leeds scales for the self-assessment of anxiety and depression. Br J Psychiatry 1976;128:156-165.
31. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
32. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
33. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
34. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-1028.
35. Schwab RS, England RC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillinghan FH, Donaldson MC, editors. Third Symposium on Parkinson's Disease. Edinburgh, UK: Livingstone; 1969:152-157.
36. Wenzelburger R, Zhang BR, Pohle S, et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002;125(pt 4):871-879.
37. Folstein MF, Folstein SE, McHugh PR. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
38. Desrosiers J, Hebert R, Bravo G, Dutil E. The Purdue Pegboard Test: normative data for people aged 60 and over. Disabil Rehabil 1995;17:217-224.
39. Boesveldt S, Verbaan D, Knol DL, van Hilten JJ, Berendse HW. Odour identification and discrimination in Dutch adults over 45 years. Rhinology 2008;46:131-136.
40. Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther 2000;80:896-903.
41. Tsigilis N, Douda H, Tokmakidis SP. Test-retest reliability of the Eurofit test battery administered to university students. Percept Mot Skills 2002;95(3 pt 2):1295-1300.
42. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
43. Nazem S, Siderowf AD, Duda JE, et al. Montreal Cognitive Assessment performance in patients with Parkinson's disease with "normal" global cognition according to Mini-Mental State Examination score. J Am Geriatr Soc 2009;57:304-308.
44. Strauss E, Sherman EMS, Spreen O, editors. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York: Oxford University Press; 2006.
45. Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011;77:1272-1275.
46. Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 2012;25:208-214.
47. Reddon JR, Gill DM, Gauk SE, Maerz MD. Purdue Pegboard: test-retest estimates. Percept Mot Skills 1988;66:503-506.
48. Kluger A, Gianutsos JG, Golomb J, et al. Patterns of motor impairment in normal ageing, mild cognitive decline and early Alzheimer's disease. J Gerontol 1997;528:28-39.
49. Scherder E, Dekker W, Eggemont L. Higher-level hand motor function in aging and (preclinical) dementia: its relationship with (instrumental) activities of daily life-a mini-review. Gerontology 2008;54:333-341.
50. Ganga G, Alty JE, Clissold BG, et al. Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase. Mov Disord 2013;28:476-481.
51. Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA. Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes. Mov Disord 2005;20:410-415.
52. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry 2002;72:721-725.
53. Bohnen NI, Muller MI, Koeppe RA, et al. History of falls in Parkinson's disease is associated with reduced cholinergic activity. Neurology 2009;73:1670-1676.
54. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat Disord 2009;15:490-494.
55. Kareken DA, Mosnik DM, Doty RL, Dzemidzic M, Hutchins GD. Functional anatomy of human odor sensation, discrimination, and identification in health and ageing. Neuropsychology 2003;17:482-495.
56. Potagas C, Dellatolas G, Ziegler M, et al. Clinical assessment of olfactory dysfunction in Parkinson's disease. Mov Disord 1998;13:394-399.
57. Swan GE, Carmelli D. Impaired olfaction predicts cognitive decline in nondemented older adults. Neuroepidemiology 2002;21:58-67.
58. Wilson RS, Arnold SE, Schneider JA, Bennett DA. The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry 2007;78:30-35.
59. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 1991;148:357-360.
60. Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012;135(pt 1):161-169.
61. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomography study. Arch Neurol 2003;60:1745-1748.
62. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson's disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722.
63. Marder K, Tang M-X, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
64. Lieberman A. Are dementia and depression in Parkinson's disease related? J Neurol Sci 2006;248:138-142.
65. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry 1990;53:597-602.
66. Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007;78:641-643.
67. Gallacher J, Bayer A, Fish M, et al. Does anxiety affect risk of dementia? Findings from the Caerphilly Prospective Study. Psychosom Med 1999;71:659-666.
68. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RHS. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
69. Levy G, Schupf N, Tang M-X, Cote LJ, Louis ED. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002;51:722-729.
70. Breteler MB, de Groot RM, van Romunde LKJ, Hofman A. Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma. Am J Epidemiol 1995;142:1300-1305.
71. Glatt SL, Hubble JP, Lyons KE, et al. Risk factors for dementia in Parkinson's disease: effect of education. Neuroepidemiology 1996;15:20-25.